~~<i id='B0AFE3BB64'><strike id='B0AFE3BB64'><tt id='B0AFE3BB64'><pre id='B0AFE3BB64'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：entertainment 2025-10-06 13:30:41 Page View：492

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Meadows told special counsel he could not recall Trump ever declassifying Mar
Next article： Tori Bowie and the unacceptable rates of Black maternal death

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Hospital at home shows how to bring innovation to health care

Acommunityparamedictakesthetemperatureofan88-year-oldpatientduringahomewellnesscheckinHawthorne,N.Y.

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Extensive review finds private equity owners jack up cost of care

AdobePrivateequityfirmsarerapidlybuyingtheirwayintotheU.S.healthcaresystem,andastheydo,newresearchfi